Sunitinib

Manufactured by Cayman Chemical

Sourced in United States

Sunitinib is a laboratory reagent used as a protein kinase inhibitor. It is a small-molecule tyrosine kinase inhibitor that targets multiple receptor tyrosine kinases involved in tumor angiogenesis, tumor growth, and tumor progression.

Automatically generated - may contain errors

Lab products found in correlation

6 protocols using sunitinib

Anticancer Drugs Screening on hESCs

Check if the same lab product or an alternative is used in the 5 most similar protocols

All 10 anticancer drugs were selected based on their selective function and importance as drugs that are frequently used in the clinic. Ten drug concentrations were tested for each drug. hESC cells were grown on a 96 well plates in a triplicate manner. hESC density was 15,000 cells per well. For each drug, six plates were used to allow six time points per concentration. The drug in each concentration was added on Day ‘0’ and the medium was replaced every 24 h. Cell viability was assessed by a CellTiter‐Glo luminescent cell viability assay according to the manufacturer's instructions (Promega) and cell viability was monitored following 1, 2, 3, 6, 10 and 13 days. Luminescence reads for the target genes were normalized to control conditions, and the replicate experiments were averaged. This comprehensive calibration regime allowed a careful selection of concentrations that produce significant cell death yet allow some cell recovery. All anticancer drugs in this study: Azacytidine, Bleomycin, Vorinostat, Imatinib, Sunitinib, Vemurafenib, Methotrexate, Olaparib, Ibrutinib and Enzalutamide, were purchased from Cayman Chemical (Ann Arbor, Michigan, USA). Preparations of all drugs were done according to vendor protocols.

Segal E., Nissenbaum J., Peretz M., Golan‐Lev T., Cashman R., Philip H., Reubinoff B.E., Kopper O, & Benvenisty N. (2023). Genome‐wide screen for anticancer drug resistance in haploid human embryonic stem cells. Cell Proliferation, 56(6), e13475.

+ Open protocol

+ Expand

Biochemical Assay Reagent Sourcing

Check if the same lab product or an alternative is used in the 5 most similar protocols

LDL, HDL, and VLDL were obtained from Lee Biosolutions (Maryland Heights, MO, USA). Cabozantinib, sunitinib, axitinib, pazopanib, U18666A, and posaconazole were obtained from Cayman Chemical Company (Ann Arbor, MI, USA). Antibody against AR was obtained from Cell Signaling Technology (Danvers, MA, USA).

Fazliyeva R., Makhov P., Uzzo R.G, & Kolenko V.M. (2024). Targeting NPC1 in Renal Cell Carcinoma. Cancers, 16(3), 517.

+ Open protocol

+ Expand

Molecular Profiling of Cancer Targets

Check if the same lab product or an alternative is used in the 5 most similar protocols

Sunitinib (#13159) and lonafarnib (#11746) were obtained from Cayman Chemical Company (Ann Arbor, MI). Anti-FNTB (#ab109625) antibody was obtained from Abcam (Cambridge, UK). Anti-β-actin (#3700), SETD2 (23486) and anti-PBRM1 (91894) antibodies were obtained from Cell Signaling Technology, (Danvers, MA). Anti-BAP1(sc-28383) antibody was obtained from Santa Cruz (Dallas, TX).

Makhov P., Sohn J.A., Serebriiskii I.G., Fazliyeva R., Khazak V., Boumber Y., Uzzo R.G, & Kolenko V.M. (2020). CRISPR/Cas9 genome-wide loss-of-function screening identifies druggable cellular factors involved in sunitinib resistance in renal cell carcinoma. British Journal of Cancer, 123(12), 1749-1756.

+ Open protocol

+ Expand

Evaluating Sunitinib and EZH2 Inhibitor Combination in Renal Cell Carcinoma

Check if the same lab product or an alternative is used in the 5 most similar protocols

786-0 and 786-0R cells were seeded in 24 wells plates (Santa Cruz biotechnology, Dallas, Texas) and allowed to attach for 24 hours. Afterwards, cells were treated with increases concentrations of sunitinib (LC laboratories, Woburn, MA), the EZH2 inhibitor GSK126 (Cayman chemical company, Ann Arbor, Michigan) or combination of both sunitinib and GSK126 using combination index values (Calcusyn software). Cell were fixed and stained with crystal violet (Sigma Aldrich, St. Louis, MO) after 48h of treatment. Afterwards, stained cells were washed with ddH₂O to remove excess dye, air-dried and dissolved in methanol. Cells viability was quantitated by absorbance using a spectrometer at 570nm (xMarks Spectrometer, Bio-Rad). 786-0shRNA (scramble) and 786-0shEZH2 were seeded in 24 well plates and 24 hours later, cells were treated with 2μM, 4μM, 6μM and 8μM of sunitinib. After 48 hours of treatment, cells were fixed, stained and read using spectrometer.

Adelaiye R., Ciamporcero E., Miles K.M., Sotomayor P., Bard J., Tsompana M., Conroy D., Shen L., Ramakrishnan S., Ku S.Y., Orillion A., Prey J., Fetterly G., Buck M., Chintala S., Bjarnason G.A, & Pili R. (2014). Sunitinib dose-escalation overcomes transient resistance in clear cell renal cell carcinoma and is associated with epigenetic modifications. Molecular cancer therapeutics, 14(2), 513-522.

+ Open protocol

+ Expand

Kinase Inhibitor Screening Protocol

Check if the same lab product or an alternative is used in the 5 most similar protocols

All chemical solvents, salts, and buffers were purchased from Thermo Scientific (Waltham, MA, USA). The following TKIs were purchased from Cayman Chemical (Ann Arbor, Michigan, USA): erlotinib, gefitinib, imatinib, LAP, nilotinib, SOR, and sunitinib. KCA was purchased from Millipore-Sigma (St Louis, MO, USA).

Tilton R.C., Barden D, & Sand M. (2001). Culture of Borrelia burgdorferi. Journal of Clinical Microbiology, 39(7), 2747.

+ Open protocol

+ Expand

Inhibitor Screen for sEV Uptake

Check if the same lab product or an alternative is used in the 5 most similar protocols

HFFF2 recipient cells were treated with several inhibitors at the below concentrations simultaneously with sEV in medium supplemented with 10% (v/v) EV‐depleted FBS and 1% (v/v) A/A for 72 h. Treatment with inhibitors and sEV was repeated 72 h later and readout was determined after 72 h.
Small molecule inhibitor concentrations used for the screen: 40 µM PD98059 (targeting MEK1/2; ThermoFisher), 20 µM SB202190 (p38MAPK; Santa Cruz Biotech), 4µ M TGFB‐R1 (TGFBR1 kinase; Calbiochem), 8 µM VEGFR2 (VEGFR2; Calbiochem), 150 nM GSK429286A (ROCK1/2, Rho‐associated kinase; Abcam), 50 nM CPD22 (ILK, integrin‐linked kinase; Calbiochem), 1 µM CPG (MNK1/2; Calbiochem), 100 nM TORIN2 (mTOR, mammalian target of rapamycin; CAYMAN Chemical), 1µM RUXOLITINIB (JAK1/2 inhibitor; CAYMAN Chemical), 40 µM AG‐490 (JAK2/3 kinase; CAYMAN Chemical), 45 µM JANEX1 (JAK3 kinase; CAYMAN Chemical), 1 µM AG‐879 (protein Tyrosine Kinase; CAYMAN Chemical), 2 µM IMATINIB (tyrosine kinase; TK1; CAYMAN Chemical), 20 µM CAY10576 (IKKε, IκB kinase episilon; CAYMAN Chemical), 1.5 µM SUNITINIB (multi tyrosine kinase, multi‐TK; CAYMAN Chemical). Additional small molecular inhibitors used: 10 µM MLN120B (IKKβ, IκB kinase beta; MedChemExpress) and 10 µM BAY11‐7082 (IKKα/β, IκB kinase alpha/beta; Sigma‐Aldrich). Other pharmacological products: lymphotoxin‐β (Sigma Aldrich‐T7799) and Cisplatin (PHR1624; Sigma‐Aldrich).

Fafián‐Labora J.A, & O’Loghlen A. (2021). NF‐κB/IKK activation by small extracellular vesicles within the SASP. Aging Cell, 20(7), e13426.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!